Openbookopenbook
Equity
Immatics NV(IMTX)
USD --+0.00%
Reward61Moderate
Risk45Moderate
📊75%Data
Thin -142% profit margin · Revenue down 90% YoY
IMTX
+0.0 · +0.00%
USD · NASDAQ
Immatics NV | Healthcare
Quality Compounder
Market Cap:1.38Bn
ℹ️
Reward Rating
61
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
45
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on IMTX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: €19.38.

What is Immatics NV?

, a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.

IMTX · Verdict

Solid reward · moderate risk

IMTX stands out on balance sheet and growth, but watch the cash flow signal.

Based on 88% data coverage

IMTX · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet99/100

    Interest covered 25.1×

  • Growth74/100

    Revenue +64.9% CAGR

Watchouts 2

  • Cash flow21/100

    -112% free-cash-flow margin

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Immatics NV?

, a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.38B.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (61)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.38B
P/E RatioN/A
Dividend YieldN/A
52 Week High12.41
52 Week Low3.3
Last AnnualDecember
IPO Date7/2/2020
IncorporatedUSA
Shares Outstanding134M
No. of Employees645
IndustryBiotechnology
ExchangeNASDAQ
Beta1.361
CurrencyUSD · Reports in EUR
Websitewww.immatics.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.